Skip to content

Biohaven BHVN Short-Term Investments

Short-Term Investments at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$548.88M+26.8%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$398.73M+75.1%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$196.28M-62.1%
uniQure logo
uniQureQURE
$446.56M+133%
Roivant Sciences logo
Roivant SciencesROIV
$2.87B+32.3%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$354.07M-18.5%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%
Enterprise value$2.26B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's short-term investments?
Biohaven (BHVN) reported short-term investments of $74.74M in Q1 2026.
How has Biohaven's short-term investments changed year-over-year?
Biohaven's short-term investments decreased by 66.7% year-over-year, from $224.33M to $74.74M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.